Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Sciences profile

Dr Hesham Al-Sallami

PositionPharmacy Programmes Admissions Co-ordinator, Senior Lecturer
QualificationsBPharm MClinPharm PhD
Research summaryClinical practice, clinical pharmacology, clinical education
TeachingClinical Pharmacy practice and clinical pharmacology
Memberships
  • Registered Pharmacist, RegPharmNZ
  • Chair of the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT NZ)
  • Executive committee member of the Population Approach Group in Australia and New Zealand (PAGANZ)
  • Member of the Otago Medical Research Foundation Scientific Committee
  • Board member of the British Pharmacological Society (BPS) International Advisory Board
ClinicalLocum pharmacist (community and hospital pharmacy)

Research

My area of research is Clinical Pharmacy Practice with a focus on the individualisation of pharmacotherapy in order to optimise patient clinical outcomes. My research focus is drug dosing in relation to body composition in children and in obese individuals. The clinical application of my research has been in the areas of anticoagulation and in insulin dosing in diabetes. My research interests also include clinical pharmacy education and pharmacists’ professional competency.

Publications

Bahnasawy, S., Al-Sallami, H., & Duffull, S. (2020). A minimal model to describe short-term haemodynamic changes of the cardiovascular system. British Journal of Clinical Pharmacology. Advance online publication. doi: 10.1111/bcp.14541

Sinha, J., Duffull, S. B., Green, B., & Al-Sallami, H. S. (2020). Evaluating the relationship between lean liver volume and fat-free mass. Clinical Pharmacokinetics, 59, 475-483. doi: 10.1007/s40262-019-00824-7

Mooranian, A., Wagle, S. R., Kovacevic, B., Takechi, R., Mamo, J., Lam, V., … Al-Sallami, H., & Al-Salami, H. (2020). Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 10, 106. doi: 10.1038/s41598-019-53999-1

Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2020). An extension of Janmahasatian’s Fat-Free Mass model for universal application across populations of different ethnicities. Clinical Pharmacokinetics. Advance online publication. doi: 10.1007/s40262-020-00883-1

Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2020). Authors' reply to Friesen: "An extension of Janmahasatian's Fat-Free Mass Model for universal application across populations of different ethnicities". Clinical Pharmacokinetics. Advance online publication. doi: 10.1007/s40262-020-00906-x

Journal - Research Article

Bahnasawy, S., Al-Sallami, H., & Duffull, S. (2020). A minimal model to describe short-term haemodynamic changes of the cardiovascular system. British Journal of Clinical Pharmacology. Advance online publication. doi: 10.1111/bcp.14541

Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2020). An extension of Janmahasatian’s Fat-Free Mass model for universal application across populations of different ethnicities. Clinical Pharmacokinetics. Advance online publication. doi: 10.1007/s40262-020-00883-1

Mooranian, A., Wagle, S. R., Kovacevic, B., Takechi, R., Mamo, J., Lam, V., … Al-Sallami, H., & Al-Salami, H. (2020). Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 10, 106. doi: 10.1038/s41598-019-53999-1

Sinha, J., Duffull, S. B., Green, B., & Al-Sallami, H. S. (2020). Evaluating the relationship between lean liver volume and fat-free mass. Clinical Pharmacokinetics, 59, 475-483. doi: 10.1007/s40262-019-00824-7

Abdul Aziz, Y. H., Al-Sallami, H. S., Wiltshire, E., Rayns, J., Willis, J., McClintock, J., Medlicott, N., Wheeler, B. J., the Paediatric Society of New Zealand Diabetes Clinical Network. (2019). Insulin pump initiation and education for children and adolescents: A qualitative study of current practice in New Zealand. Journal of Diabetes & Metabolic Disorders, 18, 59-64. doi: 10.1007/s40200-019-00390-6

Majid, A., Blackwell, M., Broadbent, R. S., Barker, D. P., Al-Sallami, H. S., Edmonds, L., Kerruish, N., & Wheeler, B. J. (2019). Newborn vitamin K prophylaxis: A historical perspective to understand modern barriers to uptake. Hospital Pediatrics, 9(1), 55-60. doi: 10.1542/hpeds.2018-0104

Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2019). Choosing the allometric exponent in covariate model building. Clinical Pharmacokinetics, 28(1), 89-100. doi: 10.1007/s40262-018-0667-0

Dowd, L. A., Wheeler, B. J., Al-Sallami, H. S., Broadbent, R. S., Edmonds, L. K., & Medlicott, N. J. (2019). Paracetamol treatment for patent ductus arteriosus: Practice and attitudes in Australia and New Zealand. Journal of Maternal-Fetal & Neonatal Medicine, 32(18), 3039-3044. doi: 10.1080/14767058.2018.1456520

Mooranian, A., Zamani, N., Luna, G., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., … Al-Salami, H. (2019). Bile acid-polymer-probucol microparticles: Protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine mode. Pharmaceutical Development & Technology, 24(10), 1272-1277. doi: 10.1080/10837450.2019.1665069

Mooranian, A., Zamani, N., Takechi, R., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., … Al-Salami, H. (2018). Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artificial Cells, Nanomedicine, & Biotechnology, 46(Suppl. 3), S748-S754. doi: 10.1080/21691401.2018.1511572

Muller, M., Wheeler, B. J., Blackwell, M., Colas, M., Reith, D. M., Medlicott, N. J., & Al-Sallami, H. S. (2018). The influence of patient variables on insulin total daily dose in paediatric inpatients with new onset type 1 diabetes mellitus. Journal of Diabetes & Metabolic Disorders, 17, 159-163. doi: 10.1007/s40200-018-0355-5

Al-Sallami, H., & Loke, S.-K. (2018). Learning a complex dose–response relationship with the computer simulation CoaguSim. Currents in Pharmacy Teaching & Learning, 10, 1406-1413. doi: 10.1016/j.cptl.2018.07.009

Mooranian, A., Negrulj, R., Takechi, R., Mamo, J., Al-Sallami, H., & Al-Salami, H. (2018). The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: Potential hypoglycaemic and anti-inflammatory effects. Drug Delivery & Translational Research, 8(3), 543-551. doi: 10.1007/s13346-017-0473-5

Gogoi-Tiwari, J., Williams, V., Waryah, C. B., Costantino, P., Al-Salami, H., Mathavan, S., … Al-Sallami, H., & Mukkur, T. (2017). Mammary gland pathology subsequent to acute infection with strong versus weak biofilm forming Staphylococcus aureus bovine mastitis isolates: A pilot study using non-invasive mouse mastitis model. PLoS ONE, 12(1), e0170668. doi: 10.1371/journal.pone.0170668

Selvakumar, D., Al-Sallami, H. S., de Bock, M., Ambler, G. R., Benitez-Aguirre, P., Wiltshire, E., … Willis, J., Wheeler, B. J., on behalf of the Paediatric Society of New Zealand Diabetes Clinical Network. (2017). Insulin regimens for newly diagnosed children with type 1 diabetes mellitus in Australia and New Zealand: A survey of current practice. Journal of Paediatrics & Child Health, 53(12), 1208-1214. doi: 10.1111/jpc.13631

Al-Sallami, H., Newall, F., Monagle, P., Ignjatovic, V., Cranswick, N., & Duffull, S. (2016). Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients. British Journal of Clinical Pharmacology, 82(1), 178-184. doi: 10.1111/bcp.12930

Tordoff, J. M., Ailabouni, N. J., Browne, D. P., Al-Sallami, H. S., & Gray, A. R. (2016). Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand. International Journal of Clinical Pharmacy, 38(4), 941-949. doi: 10.1007/s11096-016-0318-1

Negrulj, R., Mooranian, A., Chen-Tan, N., Al-Sallami, H. S., Mikov, M., Golocorbin-Kon, S., … Al-Salami, H. (2016). Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artificial Cells, Nanomedicine, & Biotechnology, 44(5), 1290-1297. doi: 10.3109/21691401.2015.1024845

Al-Sallami, H. S., & Medlicott, N. J. (2015). Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma. Journal of Pharmacy & Pharmacology, 67(2), 209-214. doi: 10.1111/jphp.12333

Mooranian, A., Negrulj, R., Al-Sallami, H. S., Fang, Z., Mikov, M., Golocorbin-Kon, S., … Al-Salami, H. (2015). Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech, 16(1), 45-52. doi: 10.1208/s12249-014-0205-9

Mooranian, A., Negrulj, R., Al-Sallami, H. S., Fang, Z., Mikov, M., Golocorbin-Kon, S., … Al-Salami, H. (2015). Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. Journal of Microencapsulation, 32(2), 151-156. doi: 10.3109/02652048.2014.958204

Al-Sallami, H. S., Goulding, A., Grant, A., Taylor, R., Holford, N., & Duffull, S. B. (2015). Prediction of fat-free mass in children. Clinical Pharmacokinetics, 54(11), 1169-1178. doi: 10.1007/s40262-015-0277-z

Mooranian, A., Negrulj, R., Chen-Tan, N., Al-Sallami, H. S., Fang, Z., Mukkur, T. K., Mikov, M., … Al-Salami, H. (2014). Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design, Development & Therapy, 8, 1221-1230. doi: 10.2147/dddt.s67349

Mooranian, A., Negrulj, R., Chen-Tan, N., Al-Sallami, H. S., Fang, Z., Mukkur, T., Mikov, M., … Al-Salami, H. (2014). Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A characterization study. Drug Design, Development & Therapy, 8, 1003-1012. doi: 10.2147/dddt.s65396

Loke, S.-K., Al-Sallami, H. S., Wright, D. F. B., McDonald, J., Jadhav, S., & Duffull, S. B. (2012). Challenges in integrating a complex systems computer simulation in class: An educational design research. Australasian Journal of Educational Technology, 28(4), 671-683. doi: 10.14742/ajet.834

Wright, D. F. B., Pavan Kumar, V. V., Al-Sallami, H. S., & Duffull, S. B. (2011). The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: Simulations from a pharmacokinetic—pharmacodynamic model. Basic & Clinical Pharmacology & Toxicology, 109(6), 494-498. doi: 10.1111/j.1742-7843.2011.00757.x

Wright, D. F. B., Al-Sallami, H. S., Jackson, P. M., & Reith, D. M. (2010). Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters (portacaths). British Journal of Clinical Pharmacology, 70(5), 769-772. doi: 10.1111/j.1365-2125.2010.03749.x

Al-Sallami, H. S., Barras, M. A., Green, B., & Duffull, S. B. (2010). Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clinical Pharmacokinetics, 49(9), 567-571. doi: 10.2165/11532960-000000000-00000

Al-Sallami, H. S., Kumar, V. V. P., Landersdorfer, C. B., Bulitta, J. B., & Duffull, S. B. (2009). The time course of drug effects. Pharmaceutical Statistics, 8, 176-185. doi: 10.1002/pst.393

Al-Sallami, H., Ferguson, R., Wilkins, G., Gray, A., & Medlicott, N. J. (2008). Bleeding events in patients receiving enoxaparin for the management of non-ST-elevation acute coronary syndrome (NSTEACS) at Dunedin Public Hospital, New Zealand. New Zealand Medical Journal, 121(1285). Retrieved from http://journal.nzma.org.nz/journal/121-1285/3342/content.pdf

Al-Sallami, H., Ball, P. A., & Davey, A. (2001). Metered-dose inhaler with spacer versus nebuliser for acute exacerbation of asthma - a literature review. Australian Journal of Hospital Pharmacy, 31(3), 189-192.

^ Top of page

Journal - Research Other

Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2020). Authors' reply to Friesen: "An extension of Janmahasatian's Fat-Free Mass Model for universal application across populations of different ethnicities". Clinical Pharmacokinetics. Advance online publication. doi: 10.1007/s40262-020-00906-x

Derbalah, A., Al-Sallami, H., Hasegawa, C., Gulati, A., & Duffull, S. B. (2020). A framework for simplification of quantitative systems pharmacology models in clinical pharmacology. British Journal of Clinical Pharmacology. Advance online publication. doi: 10.1111/bcp.14451

Sinha, J., Duffull, S. B., Green, B., & Al-Sallami, H. S. (2020). Evaluating lean liver volume as a potential scaler for in vitro-in vivo extrapolation of drug clearance in obesity using the model drug antipyrine. Current Drug Metabolism. Advance online publication. doi: 10.2174/1389200221666200515105800

Derbalah, A., Duffull, S., Newall, F., Moynihan, K., & Al-Sallami, H. (2019). Revisiting the pharmacology of unfractionated heparin. Clinical Pharmacokinetics, 58(8), 1015-1028. doi: 10.1007/s40262-019-00751-7

Mooranian, A., Zamani, N., Takechi, R., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., … Al-Salami, H. (2019). Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Therapeutic Delivery, 10(9), 563-571. doi: 10.4155/tde-2019-0052

Hennig, S., Hannam, J. A., Kirkpatrick, C. M. J., Staatz, C. E., Holford, S., Duffull, S. B., Al-Sallami, H. S., … Foster, D. J. R. (2019). Pharmacometrics in Australasia: Twenty years of Population Approach Group of Australia and New Zealand. CPT: Pharmacometrics & Systems Pharmacology, 8(10), 701-704. doi: 10.1002/psp4.12460

Reith, D. M., & Al-Sallami, H. S. (2018). Comment on van Rongen et al., "Higher midazolam clearance in obese adolescents compared with morbidly obese adults". Clinical Pharmacokinetics, 57, 1355. doi: 10.1007/s40262-018-0691-0

Sinha, J., Duffull, S. B., & Al-Sallami, H. S. (2018). A review of the methods and associated mathematical models used in the measurement of fat-free mass. Clinical Pharmacokinetics, 57(7), 781-795. doi: 10.1007/s40262-017-0622-5

Al-Sallami, H. S., Cheah, S. L., Han, S. Y., Liew, J., Lim, J., Ng, M. A., Solanki, H., Soo, R. J., Tan, V., & Duffull, S. B. (2014). Between-subject variability: Should high be the new normal? European Journal of Clinical Pharmacology, 70(11), 1403-1404. doi: 10.1007/s00228-014-1740-8

Wright, D. F. B., Al-Sallami, H. S., & Duffull, S. B. (2013). Is the dose of dabigatran really more predictable than warfarin? British Journal of Clinical Pharmacology, 76(6), 997-998. doi: 10.1111/bcp.12144

Duffull, S. B., Wright, D. F. B., Al-Sallami, H. S., Zufferey, P. J., & Faed, J. M. (2012). Dabigatran: Rational dose individualisation and monitoring guidance is needed. New Zealand Medical Journal, 125(1357). Retrieved from http://www.nzma.org.nz/journal

Al-Sallami, H., Jordan, S., Ferguson, R., Medlicott, N. J., Schollum, J., & Duffull, S. B. (2010). Current enoxaparin dosing guidelines have dubious credibility [Viewpoint]. New Zealand Medical Journal, 123(1313). Retrieved from http://journal.nzma.org.nz/journal/123-1313/4076/content.pdf

More publications...